A5018701322- Cancer Treatment and Pharmacology
- Breast Cancer Treatment Studies
- Advanced Breast Cancer Therapies
- HER2/EGFR in Cancer Research
- Lung Cancer Treatments and Mutations
- Lymphoma Diagnosis and Treatment
- Estrogen and related hormone effects
- Lung Cancer Research Studies
- Economic and Financial Impacts of Cancer
- Chronic Lymphocytic Leukemia Research
- Ovarian cancer diagnosis and treatment
- Colorectal Cancer Treatments and Studies
- CAR-T cell therapy research
- Global Cancer Incidence and Screening
- Cancer Immunotherapy and Biomarkers
- Occupational and environmental lung diseases
- Cancer survivorship and care
- Cutaneous Melanoma Detection and Management
- Chemotherapy-related skin toxicity
- Cancer therapeutics and mechanisms
- Chemotherapy-induced cardiotoxicity and mitigation
- Neuroendocrine Tumor Research Advances
- Peptidase Inhibition and Analysis
- Melanoma and MAPK Pathways
- BRCA gene mutations in cancer
Tel Aviv Sourasky Medical Center
2023
The Medical Oncology Centre of Rosebank
2011-2020
University of Pretoria
1986-2017
Wits University Donald Gordon Medical Centre
2017
Frontier Science Foundation
2017
Harvard University
2017
Dana-Farber Cancer Institute
2017
Kantonsspital Münsterlingen
2009-2015
Kantonsspital Aarau
2009-2015
Kantonsspital St. Gallen
2009-2015
Advanced Breast Cancer (ABC) comprises both locally advanced (LABC) and metastatic breast cancer (MBC) [1]. Although treatable, MBC remains an incurable disease with a median overall survival of ∼2–3 years 5-year only ∼25% [2–4]. Some more recent series seem to indicate improvement in [5, 6].
This phase III study compared docetaxel and doxorubicin in patients with metastatic breast cancer who had received previous alkylating agent-containing chemotherapy.Patients were randomized to receive an intravenous infusion of 100 mg/m(2) or 75 every 3 weeks for a maximum seven treatment cycles.A total 326 randomized, 165 161 docetaxel. Overall, produced significantly higher rate objective response than did (47.8% v 33.3%; P =.008). Docetaxel was also more active negative prognostic...
Advanced breast cancer (ABC) is a treatable but still generally incurable disease. The goals of care are to optimize both length and quality life. Due continuous research, several advances have been made, particularly for the human epidermal growth factor receptor 2 (HER-2)-positive luminal-like subtypes. Notwithstanding these advances, median overall survival patients with ABC only 2–3 years, although range wide [1–5], may be longer treated in specialized institutions [6].
This randomized, multicenter, phase III study compared doxorubicin and docetaxel (AT) with cyclophosphamide (AC) as first-line chemotherapy (CT) in metastatic breast cancer (MBC).Patients (n = 429) were randomly assigned to receive 50 mg/m(2) plus 75 214) or 60 600 215) on day 1, every 3 weeks for up eight cycles.Time progression (TTP; primary end point) time treatment failure (TTF) significantly longer AT than AC (median TTP, 37.3 v 31.9 weeks; log-rank P =.014; median TTF, 25.6 23.7...
Advanced Breast Cancer (ABC) is a treatable but still generally incurable disease. The goals of care are to optimize both length and quality life. Due continuous research, several advances have been made, particularly for the HER-2-positive Luminal-like subtypes. Notwithstanding these advances, median overall survival patients with ABC only 2–3 years, although range wide [1–5], may be longer treated in specialized institutions [6]. Implementation current knowledge highly variable among...
Advanced Breast Cancer (ABC) comprises both locally advanced (LABC) and metastatic breast cancer (MBC) [1]. Although treatable, it is remains an incurable disease with a median overall survival of ∼2–3 years 5-year only ∼25% [2–4]. Some more recent series seem to indicate improvement in [5,6].
This manuscript describes the Advanced Breast Cancer (ABC) international consensus guidelines updated at last two ABC conferences (ABC 6 in 2021, virtual, and 7 2023, Lisbon, Portugal), organized by Global Alliance. It provides main recommendations on how to best manage patients with advanced breast cancer (inoperable locally or metastatic), of all subtypes, as well palliative supportive care. These are based available evidence expert opinion when a higher level is lacking. Each guideline...
From 1965 to 1985, 262 patients with malignant pleural mesothelioma were treated cytostatics only; radiotherapy (RT); RT and cytostatics; or decortication plus cytostatics. The median survival (MS) from diagnosis was 9.6 months. This similar for all comparable treatment groups. In a univariate analysis, significant favorable prognostic factors good performance status (PS), duration of symptoms greater than 6 months at the time diagnosis, early stage disease, white race, female sex....
Purpose We report the long-term results of a randomized clinical trial comparing induction therapy with once per week for 4 weeks single-agent rituximab alone versus followed by cycles maintenance every 2 months in patients follicular lymphoma. Patients and Methods (prior chemotherapy 138; chemotherapy-naive 64) received if nonprogressive, were randomly assigned to no further treatment (observation) or four additional doses given at 2-month intervals (prolonged exposure). Results At median...
Purpose To describe benefits and toxicities of adjuvant endocrine therapies in women younger than 35 years with breast cancer (n = 582) enrolled the Suppression Ovarian Function Trial (SOFT) Tamoxifen Exemestane (TEXT). Methods In SOFT, still premenopausal after surgery or without chemotherapy were randomly assigned to tamoxifen alone, plus ovarian function suppression (OFS), exemestane OFS. TEXT, all received OFS concomitant We summarize treatment efficacy, quality life, adherence cohort...
This is the first international, multi-centre, double-blind, randomised, parallel group study to directly compare efficacy and safety profile of a single intravenous dose ondansetron (8 or 32 mg) with granisetron (3 in control cisplatin-induced acute emesis. A total 496 patients were randomised receive one three anti-emetic treatments prior cisplatin chemotherapy (≥50 mg/m2). Of these, 165 162 received 8 mg ondansetron, respectively, 169 3 granisetron. Complete emesis (0 emetic episodes)...
A key determinant of breast cancer outcome is the degree to which newly diagnosed cancers are treated correctly in a timely fashion. Available resources must be applied rational manner optimize population-based outcomes. multidisciplinary international panel experts addressed implementation treatment guidelines and developed process checklists for surgery, radiation treatment, systemic therapy. The needed stage I, II, locally advanced, metastatic were outlined, metrics developed. ability...
Purpose Rituximab maintenance therapy has been shown to improve progression-free survival in patients with follicular lymphoma; however, the optimal duration of treatment remains unknown. Patients and Methods Two hundred seventy untreated, relapsed, stable, or chemotherapy-resistant lymphoma were treated four doses rituximab monotherapy weekly intervals (375 mg/m 2 ). achieving at least a partial response randomly assigned receive one infusion every months, either on short-term schedule...
The management of locally advanced breast cancer (LABC) is guided by scientific advances but limited local resources and expertise. LABC remains very common in low-resource countries. Systemic Therapy Focus Group met as part the Breast Health Global Initiative (BHGI) Summit Budapest, Hungary, October 2007 to discuss implementation primary systemic therapy (PST) for LABC. PST standard treatment large operable enhanced-resource settings and, all resource settings, should be inoperable Standard...
To evaluate the single agent activity, pharmacokinetics and tolerability of novel tubulin targeted vinflunine (VFL) (320 mg m−2 q 21 days) as second-line chemotherapy in patients with metastatic breast carcinoma (MBC). All had disease progression after anthracycline/taxane (A/T) therapy. They could have received a nonanthracycline adjuvant treatment subsequently first-line A/T combination for advanced/metastatic disease; or relapsed >6 months completion therapy were treated alternative...
The aim of this multicentric phase II study was to investigate the efficacy and toxicity a combination chemotherapy containing paclitaxel (Taxol) novel compound, liposomal encapsulated doxorubicin (Caelyx), as first line therapy for patients with metastatic breast cancer. Thirty-four advanced cancer were treated 175 mg/m2 30 mg/m2, every 3 weeks. effective in 73% (ITT) (95% CI 55-86%) (7 complete 18 partial responses). Grade 3/4 toxicities documented small number patients. Two toxic deaths...
Objective: This phase II study assessed the activity and safety of pegylated liposomal doxorubicin (PLD) plus carboplatin in relapsed ovarian cancer (ROC). Method: Forty women with platinum-sensitive partially ROC were treated PLD 50 mg/m 2 area under curve 5 every 28 days this South African multicenter study. All patients who completed 3 cycles chemotherapy evaluated for response. Primary outcome was response intent-to-treat population. Results: Complete 35%, partial 32.5% (overall...